Abstract:BackgroundRegorafenib is the third line of treatment used in metastatic colon cancer. One of the most frequent adverse effects of regorafenib is thrombocytopenia that occurred as grade 4 in only 0.4% of patients treated in the CORRECT trial.PurposeTo describe the relationship between the occurrence of severe thrombocytopenia in a patient with metastatic colon cancer treated with regorafenib.Material and methodsThe physician reported to our pharmacy department a severe thrombocytopenia case in a patient treated… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.